Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin Concentration

Table 2

Baseline characteristics of 14 eligible patients in prospective study.

Patient number	Age (years)	Gender	Disease extent	Dose of prior mesalazine (mg)	Severity	Rachmilewitz CAI
1	27	M	Extensive	3000	Mild	5
2	73	F	Left-sided	3000	Mild	6
3	37	M	Left-sided	2250	Mild	5
4	39	F	Extensive	3000	Mild	5
5	63	F	Extensive	2250	Moderate	10
6	33	F	Left-sided	2250	Mild	5
7	59	F	Extensive	3000	Mild	6
8	40	M	Extensive	2250	Mild	5
9	27	M	Extensive	2250	Moderate	8
10	57	M	Left-sided	2250	Moderate	7
11	27	F	Proctitis	2250	Mild	5
12	72	M	Extensive	2250	Moderate	8
13	31	F	Proctitis	2250	Mild	5
14	47	M	Left-sided	2250	Mild	5